Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01561404
Other study ID # MTOR-METAB
Secondary ID 2009-010541-31
Status Terminated
Phase Phase 4
First received March 20, 2012
Last updated April 27, 2015
Start date September 2011
Est. completion date December 2013

Study information

Verified date April 2015
Source Hospital Universitari de Bellvitge
Contact n/a
Is FDA regulated No
Health authority Spain: Spanish Agency of Medicines
Study type Interventional

Clinical Trial Summary

This is an exploratory study based on the hypothesis that kidney transplant patients treated with an immunosuppressive therapy based on an inhibitor of the mammalian target of rapamycin (m-TOR) may increase resistance to physical exercise, which would result in an improvement in the quality of life of these patients.


Description:

The hypothesis of the present study is that, with respect to calcineurin inhibitors, the mTOR inhibitor-based immunosuppression may alter the physical exercise capacity in renal transplant patients.

This is based on recent data obtained. Regarding metabolism there is evidence that inhibition of mTOR, reduces muscle glucose utilization, as well as, increase fatty acid oxidation. On the other hand, has shown that drugs based on mTOR inhibitors in the context of excess of nutrients improves intracellular glucose uptake in skeletal muscle cells. Through these mechanisms could increase resistance to physical exercise, which would result in an improvement in the quality of life of patients. Nevertheless, there isn't any paper that has explored this hypothesis accurately.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date December 2013
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

1. Renal transplant patient's aged between 18 and 60 years old.

2. Heart rate in radial pulse and seated between 50 and 100 bpm.

3. Systolic blood pressure between 100 and 140 and diastolic between 50 to 90.

4. Absence of any clinical physical, psychological or psychiatric condition that would prevent from the protocol described follow-up.

5. Estimated glomerular filtration rate greater than 40 ml / min.

6. Proteinuria < 0.5 g / d.

7. Renal transplantation at least 6 months ago.

8. Immunosuppressant based on calcineurin inhibitors.

9. Hemoglobin > 11 g / dl.

10. Body mass index (BMI) < 35 kg/m2.

11. Indication for conversion to everolimus and granting of written informed consent.

Exclusion Criteria:

1. Diabetes mellitus

2. Treatment with erythropoiesis stimulating drugs

3. Treatment with ß blockers drugs

4. Participation in any clinical trial in the last 30 days prior to the inclusion.

5. Any other physical illness, psychological or psychiatric condition that could difficult the follow-up of the patient.

Study Design

Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Drug:
Everolimus
In patients that change of immunosuppressive therapy from calcineurin inhibitor (CNI)(tacrolimus or cyclosporine) to m-TOR (everolimus)has been clinically indicated, check if there is an increase in physical exercise capacity.

Locations

Country Name City State
Spain Nephrology Department. Hospital Universitari de Bellvitge L'Hospitalet de Llobregat Barcelone

Sponsors (1)

Lead Sponsor Collaborator
Josep M Cruzado

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Muscular strength The principal variable is the increase of the exercise capacity measured by 2 sub-varibles: muscular strenght and decrease of oxygen consumption in the tissues. Change from baseline to 6-8 weeks after m-TOR conversion No
Primary Oxygen consumption in the tissues The principal variable is the increase of the exercise capacity measured by 2 sub-varibles: muscular strenght and decrease of oxygen consumption in the tissues. Change from baseline to 6-8 weeks after m-TOR conversion No
Secondary Anthropometric measures Measure of anthropometric measures including height,weight, muscular folds( biceps, triceps, subscapular, pectoral, axillary, abdominal, suprailiac, thigh and leg) and perimeters (arm, forearm, wrist, abdominal, waist, hip, thigh, groin, thigh and leg). Change from baseline to 6-8 weeks after m-TOR conversion No
Secondary Strength of the hand Measure of the strenght of the hand will include:test of maximum strength of contraction of the palm, maximum resistance force of the palm and maximum power on a cycle ergometer for 5 seconds with a constant resistance of 50 N. Change from baseline to 6-8 weeks after m-TOR conversion No
Secondary Metabolic parameters- Cardioventilatory response Cardioventilatory response measured with respiratory rate, ventilation, oxygen consumption, carbon dioxide production, respiratory quotient and tidal volume during stress test. Change from baseline to 6-8 weeks after m-TOR conversion No
Secondary Metabolic parameters- Biochemical response Lactate and blood glucose levels after stress test Change from baseline to 6-8 weeks after m-TOR conversion No
Secondary Glucose tolerance test Change from baseline to 6-8 weeks after m-TOR conversion No
Secondary Blood pressure Continuos blood preassure measure (24 hours) with a holter monitor device. Change from baseline to 6-8 weeks after m-TOR conversion No
See also
  Status Clinical Trial Phase
Recruiting NCT06061367 - Muscles Strength and Gait Parameteres After TKA
Completed NCT04136821 - The Long-term Effects of Oceanix™ on Resistance Training Adaptations N/A
Recruiting NCT05945641 - Effect of Low-load Resistance Training vs. High-intensity Interval Training on Local Muscle Endurance N/A
Not yet recruiting NCT05510648 - Evaluation of the Effect of High-intensity Laser Therapy in Knee Osteoarthritis N/A
Completed NCT03715920 - Comparison of Different Quadriceps Femoris Isometric Strengthening Methods N/A
Completed NCT04535336 - Vitality Acupunch Exercise Program for Older Adults With Sarcopenia N/A
Completed NCT04880486 - Weight Training With VR in Out-Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease N/A
Recruiting NCT06061315 - Effect of Collagen Peptides, in Combination With Resistance Training, on Body Composition and Muscle Strength in Untrained Men N/A
Completed NCT05366348 - The Effects of Horse-back Riding on Core Muscles in Adolescents N/A
Completed NCT04213586 - Effects of Whey Protein and Collagen Supplementation N/A
Completed NCT04626817 - Effect of Oral Isotretinoin on Muscle Strength in Patients With Acne Vulgaris: A Prospective Controlled Study N/A
Completed NCT03922113 - Muscle Function After Intensive Care
Completed NCT01449097 - Adductor-Canal-Blockade Versus the Femoral Nerve Block Effect on Muscle Strength and Mobilization in Healthy Volunteers Phase 4
Completed NCT06196268 - Core Strengthening vs Pilates Exercises on Posture, Body Awareness and Fatigue Among Female Athletes N/A
Completed NCT05882981 - Increased Femoral Anteversion and Physical Performance
Completed NCT00059436 - Mental Effort and Muscle Strength Phase 1
Recruiting NCT06410014 - Assessment of Overall Functioning in Patients With Complex Health Issues
Completed NCT04315077 - The Short Term Effects of Oceanix Supplementation on Recovery N/A
Completed NCT04239417 - Effect of Preoperative Abdominal Exercises and Russian Current on Muscle Strength Post Ventral Hernioplasty N/A
Completed NCT03973060 - Effectiveness of Muscular Work and Genetic Variants in Strength Gain of Ischiofemoral and Quadriceps N/A